Foundational Supplements: Electrolytes and Hydration
For patients with autonomic dysfunction (reported in the majority of ME/CFS patients (Newton et al. 2007)), electrolyte and fluid management is often the single most impactful intervention.
1 Why Electrolytes Matter in ME/CFS
Autonomic dysfunction in ME/CFS frequently manifests as:
- Reduced blood volume (hypovolemia)
- Impaired vasoconstriction
- Excessive venous pooling
- Orthostatic intolerance
Adequate sodium, potassium, and fluid intake help maintain blood volume and support cardiovascular compensation.
2 Sodium
Rationale. Sodium increases blood volume by promoting water retention. POTS expert consensus guidelines recommend 10–12 g of salt daily (versus 2–3 g typical intake) (Sheldon et al. 2015).
Evidence. Moderate for POTS; limited ME/CFS-specific data, but widely reported helpful.
Forms.
- Table salt: Cheapest; 2.3 g sodium per teaspoon
- Electrolyte drinks: LMNT, Liquid IV, Drip Drop, Nuun—convenient but expensive
- Salt tablets: Precise dosing; some find easier than drinking salty fluids
- Oral rehydration salts (ORS): WHO formula; includes glucose for sodium-glucose cotransport
Practical Protocol.
- Add 1/4–1/2 teaspoon salt to each liter of water
- Drink before standing or activity
- Morning loading: 16–24 oz with salt before getting up
- Target: 2–3 L fluid plus 8–12 g salt daily (approximately 3–5 g elemental sodium)
Cautions.
- Check with physician if hypertension, heart failure, or kidney disease
- Some patients with hyperadrenergic POTS may worsen with excess sodium
- Monitor for edema; some is expected and indicates effectiveness
- Potential for paradoxical intracellular effects: ME/CFS patients may have baseline intracellular sodium elevation in muscle tissue (Petter et al. 2022). Rapid sodium loading could theoretically worsen intracellular sodium overload via impaired Na+/K+-ATPase function (see Section Histamine Intolerance and Electrolyte Products)
Energy Profile. Category A–B (context-dependent). Improved blood volume enhances oxygen and nutrient delivery to cells, supporting energy production. However, processing sodium via Na+/K+-ATPase consumes an estimated 20–40% of cellular ATP (Wirth and Scheibenbogen 2021). In ME/CFS patients with documented intracellular sodium overload, additional sodium loading may paradoxically increase ATPase energy demands. Net effect depends on individual pathophysiology: beneficial for hypovolemia-dominant presentation, potentially harmful if intracellular sodium is already elevated.
3 Potassium
Rationale. Intracellular potassium is essential for nerve and muscle function. Some ME/CFS patients show functional potassium deficiency even with normal serum levels.
Evidence. Theoretical; no ME/CFS-specific trials.
Forms.
- Potassium chloride: Most common; Nu-Salt, Morton Lite Salt
- Potassium citrate: Better tolerated GI-wise
- Coconut water: Natural source (\(\sim\) 600 mg per cup)
Dosing. 2,000–4,700 mg daily (food + supplements); start low.
Cautions. Excess potassium can cause cardiac arrhythmias. Do not exceed 99 mg per dose in supplement form without medical supervision. Those on ACE inhibitors, ARBs, or with kidney disease should be especially cautious.
Energy Profile. Category A (net energy provider). Essential cofactor for Na+/K+-ATPase function—without adequate potassium, the pump cannot maintain membrane potential, and cellular energy production collapses. Correcting potassium deficiency directly enables ATP-dependent cellular processes. Minimal processing overhead.
4 Magnesium
Rationale. Magnesium is a cofactor for \(>\) 300 enzymes, including ATP synthesis. Deficiency is common and underdiagnosed (serum magnesium poorly reflects tissue status). Relevant to ME/CFS because:
- Required for mitochondrial ATP production
- Modulates NMDA receptors (relevant to central sensitization)
- Supports autonomic function
- Promotes sleep (GABA-A receptor modulation)
- Calcium overload cascade — calcium-specific rationale: Mg-ATP is the true substrate of Na+/K+-ATPase (not ATP alone); Mg2+ deficiency impairs pump function, raising intracellular Na+ and driving NCX1 reversal toward Ca2+ overload (the AIMM cascade, Section:sodium-calcium-cascade). Mg2+ also acts as a physiological Ca2+ antagonist at NMDA receptors. If TRPM7 (the primary cellular Mg2+ entry channel) is dysfunctional in ME/CFS, intracellular Mg2+ depletion is an expected downstream consequence, amplifying the calcium overload cascade.
Evidence. Low–Moderate for ME/CFS; one small trial showed benefit with IM magnesium sulfate
Forms.
- Magnesium glycinate: Well-absorbed; calming; good for sleep; less GI upset
- Magnesium malate: Malic acid may support TCA cycle; often recommended for fibromyalgia
- Magnesium L-threonate: Crosses blood-brain barrier; may help cognition; expensive
- Magnesium citrate: Well-absorbed; can cause loose stools (useful if constipated)
- Magnesium oxide: Poorly absorbed; cheap; mainly useful as laxative
- Magnesium taurate: Combined with taurine; may benefit cardiovascular system
Dosing. 200–600 mg elemental magnesium daily; split doses. Start low (100–200 mg) and increase gradually. Bowel tolerance is the limiting factor for oral forms.
Practical Tip. Topical magnesium (Epsom salt baths, magnesium oil) provides modest absorption and may help with muscle symptoms, though evidence is limited.
Energy Profile. Category A (net energy provider). Required cofactor for over 300 enzymatic reactions, including ATP synthesis itself (ATP exists physiologically as Mg-ATP complex). Deficiency directly impairs energy production at multiple points: glycolysis, TCA cycle, and oxidative phosphorylation. Supplementation restores enzymatic capacity with minimal metabolic processing cost. Among the highest-priority supplements for energy-depleted patients.
Certainty: 0.35. Magnesium L-threonate is the only magnesium form demonstrated to reliably elevate brain magnesium levels in humans, crossing the blood-brain barrier via monocarboxylate transporters. Magnesium blocks the NMDA receptor channel in a voltage-dependent manner — at resting membrane potential, Mg2+ occupies the channel pore and prevents Ca2+ influx. When glutamatergic hyperexcitability depolarizes the postsynaptic membrane, Mg2+ is expelled, allowing NMDA receptor activation (Maccallini 2026). If ME/CFS involves genetically driven glutamatergic hyperexcitability (Hypothesis Glutamatergic Synaptic Dysfunction as Genetically-Driven Core Mechanism), elevating brain magnesium could raise the threshold for NMDA receptor activation, reducing excitotoxic signaling.
Dosing: 1-2 g/day magnesium L-threonate providing approximately 144-288 mg elemental magnesium. Divided doses (morning and afternoon) to maintain stable brain magnesium levels. Titrate from 1 g/day.
Safety note (no human ME/CFS data): No ME/CFS-specific trials exist for magnesium L-threonate. General magnesium safety applies: loose stools at high doses, caution in renal impairment (CrCl < 30 mL/min), potential interaction with aminoglycoside antibiotics and bisphosphonates. Magnesium L-threonate is more expensive than other magnesium forms.
Falsifiable prediction: 12-week trial of magnesium L-threonate 2 g/day vs placebo in ME/CFS patients stratified by glutamatergic PRS will show significant reduction in cognitive PEM severity and improved processing speed only in the high-glutamatergic-PRS subgroup, with effect size correlating with brain magnesium elevation measured by MRS.
5 Complete Electrolyte Formulas
Many patients find pre-mixed electrolyte formulas convenient. Key ingredients to look for:
- Sodium: 500–1000 mg per serving
- Potassium: 200–400 mg per serving
- Magnesium: 50–100 mg per serving
- Minimal or no sugar (some glucose aids sodium absorption; excessive sugar is counterproductive)
DIY Oral Rehydration Solution. > > 1 L water + 1/2 tsp salt + 1/4 tsp potassium chloride (Nu-Salt) + 2 tbsp sugar or honey + optional: squeeze of citrus Cost: pennies per liter versus $1–3 for commercial products.
Clinical evidence for ORS efficacy. Medow et al. (2019) compared ORS (1~litre over 30~minutes, orally) with intravenous saline (1~litre) in children with POTS and found similar improvement in cerebral blood flow and similar reduction in orthostatic intolerance in both groups This establishes ORS as a practical, non-invasive alternative to IV saline for blood volume expansion in dysautonomia. The mechanism exploits the intestinal sodium-glucose cotransporter (SGLT1): glucose in the ORS enables active sodium absorption in the small intestine, carrying water along osmotically. This pathway operates independently of renal sodium retention, which is impaired in ME/CFS due to RAAS suppression (see Section:blood-volume in Chapter:cardiovascular). For patients with severe hypovolemic thirst (Section:hypovolemic-thirst in Chapter:cardiovascular), consuming 70–80% of daily fluids as ORS rather than plain water can substantially reduce fluid intake while improving blood volume. Commercial products formulated for ME/CFS and POTS include Normalyte (dextrose-based, minimal additives) and Trioral Salts (lowest cost).
Long-term safety of high daily ORS consumption has not been formally studied. Some clinicians report electrolyte formulations being hard on the kidneys. ORS may further suppress RAAS activity (the body receives easy electrolyte supply, reducing endogenous retention stimulus). Tapering is recommended when discontinuing regular ORS. Do not combine high ORS intake with aggressive salt loading.
A substantial subset of ME/CFS patients have histamine intolerance (HIT) or mast cell activation syndrome (MCAS) (Afrin et al. 2017), making standard electrolyte products problematic (see Section Connections to Allergies and Mast Cell Activation for MCAS pathophysiology). Common triggers in commercial electrolyte formulas:
Ingredients to avoid with HIT/MCAS:
- Citric acid: Ubiquitous in commercial products; can trigger mast cell degranulation
- Citrus flavorings: Natural lemon, lime, orange flavors are high-histamine
- Artificial colors: Red 40, Yellow 5/6 can trigger mast cells
- Fermented ingredients: Some products contain fermented sugars
- Stevia: Triggers reactions in some sensitive individuals
HIT-safe DIY electrolyte recipe: > > 1 L filtered water + 1/2 tsp sea salt (unrefined) + 1/4 tsp potassium chloride + 1–2 tbsp maple syrup (pure, grade A) Omit citrus entirely. Maple syrup provides glucose for sodium-glucose co-transport without histamine issues. Some patients tolerate small amounts of fresh ginger for flavor.
Commercial options for HIT/MCAS:
- LMNT unflavored (citric acid-free)
- Pure Encapsulations Electrolyte/Energy Formula
- DIY remains safest option for highly sensitive patients
Note: POTS patients with HIT/MCAS face a double challenge—they need electrolytes for blood volume but react to most products. Trial elimination of problematic ingredients before assuming electrolyte intolerance. Many patients who thought they “couldn’t tolerate electrolytes” actually couldn’t tolerate citric acid or flavorings; plain salt in water may work when commercial products don’t.
6 Caution: Electrolyte Initiation in ME/CFS
Standard POTS/dysautonomia guidelines recommend high sodium intake (10–12 g/day) to expand blood volume—addressing extracellular sodium. However, emerging evidence suggests ME/CFS patients may already have intracellular sodium overload in muscle tissue, creating a potential paradox where aggressive sodium supplementation could worsen underlying pathophysiology even while improving some orthostatic symptoms (Wirth and Scheibenbogen 2021)
The Evidence.
- MRI findings (2022): Sodium MRI demonstrated elevated baseline intracellular muscle sodium in ME/CFS patients across all five lower leg muscle compartments (12.2 mM vs 9.4 mM in controls for anterior extensors, \(p=0.003\)). Post-exercise sodium accumulation was also greater (+30% vs +17% at 12 min) (Petter et al. 2022). Evidence quality: Low (single small study, \(n=6\) per group); requires replication.
- Functional correlation: Elevated muscle sodium correlated inversely with hand grip strength (\(p=0.03\), \(R^2=0.38\)), suggesting functional consequences (Petter et al. 2022).
Certainty: 0.25. Mechanistic hypothesis based on indirect evidence (elevated intracellular sodium on MRI (Petter et al. 2022), known NCX biophysics); not directly tested in ME/CFS. Wirth and Scheibenbogen propose that \(\beta_2\)-adrenergic receptor dysfunction impairs Na+/K+-ATPase activity, allowing intracellular sodium accumulation (Wirth and Scheibenbogen 2021) When intracellular sodium exceeds a threshold, the sodium-calcium exchanger (NCX) reverses direction—importing calcium instead of exporting it—causing calcium overload and mitochondrial dysfunction. This model suggests ME/CFS patients operate near the NCX reversal threshold, explaining why even minor exertion triggers post-exertional malaise.
Clinical Implications. Dietary sodium primarily affects blood volume, not intracellular muscle sodium directly. However:
- Blood volume expansion remains beneficial for most ME/CFS patients with orthostatic intolerance—the question is rate of initiation
- Rapid sodium loading during energy-depleted states could theoretically stress already-compromised Na+/K+-ATPase function
- Individual response varies—some patients tolerate high sodium well; others report worsening with aggressive supplementation
“Start Low, Go Slow” Protocol. Given the uncertainty, conservative initiation is prudent:
- Week 1: Baseline—maintain current sodium intake; establish symptom diary
- Week 2: Add 500–1000 mg sodium daily (approximately 1/4 tsp salt or one electrolyte packet)
- Weeks 3–6: If tolerated, increase by 500–1000 mg weekly
- Target: Reach 3–6 g supplemental sodium over 4–6 weeks (in addition to dietary intake)
- Monitor: Blood pressure (sitting and standing), energy levels, PEM threshold
Warning Signs—Stop or Reduce If:
- Increased muscle pain, weakness, or fatigue unexplained by activity
- New or worsening palpitations or resting tachycardia
- Worsening PEM threshold (crashing at lower activity levels)
- Sustained blood pressure \(\\>\) 130/80 mmHg at rest (Stock et al. 2022)
- Significant peripheral edema beyond mild ankle swelling
Additional Considerations.
- TRPM3 connection: ME/CFS involves TRPM3 ion channel dysfunction affecting calcium handling (Section Arginine Depletion as the Nutritional Choke-Point Linking MDSC Expansion to NK Metabolic Failure). The relationship between TRPM3 dysfunction and NCX-mediated calcium overload warrants investigation
- Energy state matters: Supplementation during crashes may be less well-tolerated than during stable periods
- Electrolyte balance: Always supplement sodium alongside potassium and magnesium
- Long-term risks: High sodium intake carries cardiovascular risks independent of blood pressure (Stock et al. 2022); regular monitoring advisable
The interaction between dietary sodium and intracellular muscle sodium in ME/CFS has not been directly studied. This caution is based on documented intracellular elevation, plausible mechanisms, and clinical reports of sodium intolerance in some patients. Prospective studies comparing titration protocols with sodium MRI endpoints would clarify this relationship.